Trial
NCT01381211
Transarterial RAdioembolization Versus ChemoEmbolization for the Treatment of Hepatocellular Carcinoma (HCC)
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
University Hospital, Ghent
Collaborators
—
Condition
Hepatocellular Carcinoma
Intervention
TACE-DEB
Why stopped
based on interim analysis results
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-12-15